Due to a system-wide technology update, we are experiencing extremely high call volume. We appreciate your patience with our operators during this time. Thank you for choosing Fox Chase Cancer Center.
Dr. Erica Huelsmann Wins a Conquer Cancer Annual Meeting Merit Award
PHILADELPHIA (June 21, 2022)—Erica Huelsmann, MD, a Gynecological Oncology Fellow at Fox Chase Cancer Center, has been awarded a 2022 Conquer Cancer Merit Award by Conquer Cancer, the ASCO Foundation. The prestigious award, given at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, supports researchers with projects that span many areas of cancer care, including precision medicine, palliative care, and breast cancer.
“We are immeasurably proud of Dr. Huelsmann and are very excited to see that her talent as a researcher and gynecologic oncologist is being recognized by Conquer Cancer,” said Christina S. Chu, MD, interim chief of the Division of Gynecologic Oncology and director of the Gynecological Oncology Fellowship at Fox Chase.
Huelsmann was one of more than 400 promising cancer researchers representing 32 countries who received part of over $12 million awarded by Conquer Cancer to accelerate cancer research.
The award recognized Huelsmann’s research, which focused on methods of prolonging disease-free intervals in advanced epithelial ovarian cancer (AEOC) patients using maintenance therapy. AEOC is the fifth most common cause of death due to cancer in women in the United States. Although there is an 80% treatment response initially in patients, most cancers recur within two years.
Huelsmann examined national approaches to front-line maintenance therapy following treatment of AEOC with PARPi, which are poly-(ADP) ribose polymerase inhibitors. The study, which she conducted with other researchers at Fox Chase, found that despite previously documented high rates of response to maintenance PARPi and increased use over time, less than 50% of patients with AEOC receive this regimen.
“Thank you to the generous Conquer Cancer donors who are supporting the remarkable group of individuals we are honoring,” said Howard A. Burris III, MD, FACP, FASCO, chair of the Conquer Cancer Board of Directors. “It is these rising leaders whose projects offer a range of creative approaches to cancer care who are working to accelerate breakthrough research and empower people everywhere to conquer cancer. While these grants and awards provide funding to explore inventive ideas and opportunities to build meaningful careers, they also offer great hope to our patients.”
Fox Chase Cancer Center (Fox Chase), which includes the Institute for Cancer Research and the American Oncologic Hospital and is a part of Temple Health, is one of the leading comprehensive cancer centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase is also one of just 10 members of the Alliance of Dedicated Cancer Centers. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nursing program has received the Magnet recognition for excellence five consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship, and community outreach. It is the policy of Fox Chase Cancer Center that there shall be no exclusion from, or participation in, and no one denied the benefits of, the delivery of quality medical care on the basis of race, ethnicity, religion, sexual orientation, gender, gender identity/expression, disability, age, ancestry, color, national origin, physical ability, level of education, or source of payment.
For more information, call 888-369-2427